Elanco Animal Health Incorporated $ELAN Shares Acquired by Corient Private Wealth LP

Key Points

• Corient Private Wealth increased its Elanco stake by 124.1% in the second quarter, bringing its holdings to 342,271 shares valued at approximately $8.4 million. Institutional investors collectively own 97.48% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $29.09; UBS recently raised its target to $33.
• Elanco exceeded quarterly expectations, reporting adjusted earnings of $0.34 per share and revenue of $1.37 billion, up 10.2% year over year. Company insiders also purchased 63,198 shares worth roughly $1.47 million during the last quarter.

Corient Private Wealth LP lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 124.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 342,271 shares of the company's stock after buying an additional 189,540 shares during the period. Corient Private Wealth LP owned 0.07% of Elanco Animal Health worth $8,423,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ELAN. BlackRock Inc. purchased a new stake in shares of Elanco Animal Health in the second quarter valued at $1,202,198,000. Primecap Management Co. CA acquired a new stake in shares of Elanco Animal Health in the second quarter worth approximately $1,118,402,000. T. Rowe Price Investment Management Inc. grew its holdings in Elanco Animal Health by 11.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company's stock valued at $797,197,000 after purchasing an additional 3,717,404 shares during the period. Geode Capital Management LLC grew its holdings in Elanco Animal Health by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company's stock valued at $213,343,000 after purchasing an additional 640,098 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in Elanco Animal Health during the second quarter worth approximately $205,636,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ELAN shares. UBS Group increased their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 22nd. Piper Sandler reaffirmed an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Weiss Ratings upgraded shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. Finally, Wall Street Zen cut shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $29.09.

Insiders Place Their Bets

In related news, Director Michael J. Harrington bought 5,000 shares of the company's stock in a transaction dated Wednesday, August 12th. The stock was bought at an average price of $21.82 per share, with a total value of $109,100.00. Following the transaction, the director owned 131,451 shares of the company's stock, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Shiv O'Neill bought 3,998 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was bought at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. This represents a 4.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by insiders.

Elanco Animal Health Stock Down 0.6%

Shares of NYSE:ELAN opened at $22.73 on Friday. The company has a market capitalization of $11.36 billion, a price-to-earnings ratio of -55.45, a price-to-earnings-growth ratio of 1.63 and a beta of 1.68. The company has a 50 day moving average of $24.39 and a two-hundred day moving average of $23.82. Elanco Animal Health Incorporated has a 52-week low of $18.45 and a 52-week high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the prior year, the firm earned $0.26 earnings per share. The business's quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts forecast that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated NYSE: ELAN is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company's products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.